nach oben

PharmacoEconomics

Erschienen in:

01.07.2009 | Review Article

Societal and Patient Burden of Fibromyalgia Syndrome

verfasst von: Prof. Lieven Annemans, Katell Le Lay, Charles Taïeb

Erschienen in: PharmacoEconomics | Ausgabe 7/2009

Einloggen, um Zugang zu erhalten

Abstract

Fibromyalgia syndrome (FMS) is an under-diagnosed disorder of unknown aetiology, characterized by chronic widespread muscular pain, often accompanied by somatic and psychological symptoms. Several studies have described the impact of FMS on patients’ functionality, disability and quality of life. Other studies have reported on the burden to patients, healthcare payers and society. This review brings the existing evidence together and concludes that the patient burden of fibromyalgia is very high in comparison with many other conditions. The burden to healthcare payers and society is important as well, and can be mostly explained by factors not directly related to the treatment of FMS. Data suggest that the cost before diagnosis may even be higher than the cost after diagnosis. It is very likely that the combination of symptoms not only complicates the recognition and treatment of FMS, but also magnifies the burden of FMS.

Despite the complex and controversial construct of this syndrome, the results in terms of patient, healthcare payer and societal burden are quite consistent.

Carville SF, Arendt-Nielsen S, Bliddal H, et al. EULAR evidence-based recommendations for the management of fibromyalgia syndrome. Ann Rheum Dis 2008; 67 (4): 536–41PubMedCrossRef

Reich JW, Johnson LM, Zautra AJ, et al. Uncertainty of illness relationships with mental health and coping processes in fibromyalgia patients. J Behav Med 2006; 29 (4): 307–16PubMedCrossRef

Mease PJ, Clauw DJ, Arnold LM, et al. Fibromyalgia syndrome. J Rheumatol 2005; 32 (11): 2270–7PubMed

Prodinger B, Cieza A, Williams DA, et al. Measuring health in patients with fibromyalgia: content comparison of questionnaires based on the International Classification of Functioning, Disability and Health. Arthritis Rheum 2008; 59 (5): 650–8PubMedCrossRef

Wolfe F, Smythe HA, Yunus MB, et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia: report of the Multicenter Criteria Committee. Arthritis Rheum 1990; 33 (2): 160–72PubMedCrossRef

Wolfe F, Ross K, Anderson J, et al. The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum 1995; 38 (1): 19–28PubMedCrossRef

White KP, Speechley M, Harth M, et al. The London Fibromyalgia Epidemiology Study: the prevalence of fibromyalgia syndrome in London, Ontario. J Rheumatol 1999; 26 (7): 1570–6PubMed

Carmona L, Ballina J, Gabriel R, et al. The burden of musculoskeletal diseases in the general population of Spain: results from a national survey. Ann Rheum Dis 2001; 60: 1040–5PubMedCrossRef

Salaffi F, De Angelis R, Grassi W, et al. Prevalence of musculoskeletal conditions in an Italian population sample: results of a regional community-based study. I: the MAPPING study. Clin Exp Rheumatol 2005; 23 (6): 819–28PubMed

10.

Branco JC, Bannwarth B, Failde I, et al. Prevalence of fibromyalgia: a survey in five European countries. Semin Arthritis Rheum. Epub 2009 Feb 26

11.

Zijlstra TR, Braakman-Jansen LM, Taal E, et al. Cost-effectiveness of spa treatment for fibromyalgia: general health improvement is not for free. Rheumatology (Oxford) 2007; 46 (9): 1454–9CrossRef

12.

Blotman F, Thomas E, Myon E, et al. Awareness and knowledge of fibromyalgia among French rheumatologists and general practitioners. Clin Exp Rheum 2005; 23: 697–700

13.

Bennett RM, Jones J, Turk DC, et al. An internet survey of 2,596 people with fibromyalgia. BMC Musculoskelet Disord 2007; 8: 27PubMedCrossRef

14.

Tüzün EH, Albayrak G, Eker L, et al. A comparison study of quality of life in women with fibromyalgia and myofascial pain syndrome. Disabil Rehabil 2004; 26 (4): 198–202PubMedCrossRef

15.

Jensen MP, Chodroff MJ, Dworkin RH. The impact of neuropathic pain on health-related quality of life: review and implications. Neurology 2007 Apr 10; 68 (15): 1178–82PubMedCrossRef

16.

Theadom A, Cropley M, Humphrey KL. Exploring the role of sleep and coping in quality of life in fibromyalgia. J Psychosom Res 2007; 62 (2): 145–51PubMedCrossRef

17.

Arnould B, Benmedjahed K, Barnes N, et al. Qualitative steps for the development of a questionnaire assessing the burden of fibromyalgia on patients’ daily lives [PMS60 poster]. ISPOR 11th Annual European Congress; 2008 Nov 8–11; Athens

18.

Offenbächer M, Cieza A, Brockow T, et al. Are the contents of treatment outcomes in fibromyalgia trials represented in the International Classification of Functioning, Disability, and Health. Clin J Pain 2007; 23 (8): 691–701PubMedCrossRef

19.

Kurtze N, Gundersen KT, Svebak S. The impact of perceived physical dysfunction, health habits and affective symptoms on employment status among fibromyalgia support group members. J Musculoskeletal Pain 2001; 9 (2): 39–53CrossRef

20.

Burckhardt CS, Clark SR, Bennett RM. The fibromyalgia impact questionnaire: development and validation. J Rheumatol 1991; 18: 728–33PubMed

21.

White KP, Speechley M, Harth M, et al. Comparing self-reported function and work disability in 100 community cases of fibromyalgia syndrome versus controls in London, Ontario: the London Fibromyalgia Epidemiology Study. Arthritis Rheum 1999; 42 (1): 76–83PubMedCrossRef

22.

White KP, Speechley M, Harth M, et al. The London Fibromyalgia Epidemiology Study: comparing the demographic and clinical characteristics in 100 random community cases of fibromyalgia versus controls. J Rheumatol 1999 Jul; 26 (7): 1577–85PubMed

23.

Nicassio PM, Moxham EG, Schuman CE, et al. The contribution of pain, reported sleep quality, and depressive symptoms to fatigue in fibromyalgia. Pain 2002; 100 (3): 271–9PubMedCrossRef

24.

Henriksson CM, Liedberg GM, Gerdle B. Women with fibromyalgia: work and rehabilitation. Disabil Rehabil 2005 Jun 17; 27 (12): 685–94PubMedCrossRef

25.

Henriksson C, Liedberg G. Factors of importance for work disability in women with fibromyalgia. J Rheumatol 2000; 27 (5): 1271–6PubMed

26.

Burckhardt CS, Clark SR, O’Reilly CA, et al. Pain-coping strategies of women with fibromyalgia: relationship to pain, fatigue, and quality of life. J Muscoskel Pain 1997; 5 (3): 5–21CrossRef

27.

Al-Allaf AW. Work disability and health system utilization in patients with fibromyalgia syndrome. J Clin Rheumatol 2007; 13 (4): 199–201PubMedCrossRef

28.

Assefi NP, Coy TV, Uslan D, et al. Financial, occupational, and personal consequences of disability in patients with chronic fatigue syndrome and fibromyalgia compared to other fatiguing conditions. J Rheumatol 2003; 30 (4): 804–8PubMed

29.

White LA, Birnbaum HG, Kaltenboeck A, et al. Employees with fibromyalgia: medical comorbidity, healthcare costs, and work loss. J Occup Environ Med 2008; 50 (1): 13–24PubMedCrossRef

30.

Evans CJ, Parthan A, Le K. Economic and humanistic burden of fibromyalgia in the USA. Expert Rev of Pharmacoecon and Outcomes Res 2006; 6 (3): 303–14CrossRef

31.

Kivimäki M, Leino-Arjas P, Kaila-Kangas L, et al. Increased absence due to sickness among employees with fibromyalgia. Ann Rheum Dis 2007; 66 (1): 65–9PubMedCrossRef

32.

Moldofsky H, Boussetta S, Le Lay K, et al. Career interruptions and sick leaves among fibromyalgia patient [THU0387 poster]. Paris: European League Against Rheumatology EULAR 2008 Jun: 11–4

33.

Verbunt JA, Pernot DH, Smeets RJ. Disability and quality of life in patients with fibromyalgia. Health Qual Life Outcomes 2008; 6: 8PubMedCrossRef

34.

Wolfe F, Michaud K. Severe rheumatoid arthritis (RA), worse outcomes, comorbid illness, and sociodemographic disadvantage characterize RA patients with fibromyalgia. J Rheumatol 2004; 31 (4): 695–700PubMed

35.

Yilmaz F, Sahin F, Ergoz E, et al. Quality of life assessments with SF 36 in different musculoskeletal diseases. Clin Rheumatol 2008; 27 (3): 327–32PubMedCrossRef

36.

Angst F, Verra ML, Lehmann S, et al. Responsiveness of five condition-specific and generic outcome assessment instruments for chronic pain. BMC Med Res Methodol 2008; 8: 26PubMedCrossRef

37.

Birtane M, Uzunca K, Taştekin N, et al. The evaluation of quality of life in fibromyalgia syndrome: a comparison with rheumatoid arthritis by using SF-36 Health Survey. Clin Rheumatol 2007; 26 (5): 679–84PubMedCrossRef

38.

Neumann L, Sukenik S, Bolotin A, et al. The effect of balneotherapy at the Dead Sea on the quality of life of patients with fibromyalgia syndrome. Clin Rheumatol 2001; 20 (1): 15–9PubMedCrossRef

39.

Pagano T, Matsutani LA, Ferreira EA, et al. Assessment of anxiety and quality of life in fibromyalgia patients. Sao Paulo Med J 2004; 122 (6): 252–8PubMedCrossRef

40.

Hoffman DL, Dukes EM. The health status burden of people with fibromyalgia: a review of studies that assessed health status with the SF-36 or the SF-12. Int J Clin Pract 2008 Jan; 62 (1): 115–26PubMedCrossRef

41.

Gusi N, Tomas-Carus P. Cost-utility of an 8-month aquatic training for women with fibromyalgia: a randomized controlled trial [abstract]. Arthritis Res Ther 2008; 10 (1): R24CrossRef

42.

Couto CI, Natour J, Carvalho AB. Fibromyalgia: its prevalence and impact on the quality of life on a hemodialyzed population. Hemodial Int 2008; 12 (1): 66–72PubMedCrossRef

43.

Löfgren M, Ekholm J, Ohman A. ‘A constant struggle’: successful strategies of women in work despite fibromyalgia. Disability Rehabil 2006; 28 (7): 447–55CrossRef

44.

Boonen A, van den Heuvel R, van Tubergen A, et al. Large differences in cost of illness and wellbeing between patients with fibromyalgia, chronic low back pain, or ankylosing spondylitis. Ann Rheum Dis 2005; 64 (3): 396–402PubMedCrossRef

45.

Maugars Y, Lamotte M, Devos C, et al. Fibromyalgia: the avoided cost of the non-diagnosed patient in France [THU0386 poster]. Paris: European League Against Rheumatology EULAR, 2008 Jun: 11–4

46.

Wolfe F, Anderson J, Harkness D, et al. A prospective, longitudinal, multicenter study of service utilization and costs in fibromyalgia. Arthritis Rheum 1997; 40 (9): 1560–70PubMedCrossRef

47.

Robinson RL, Birnbaum HG, Morley MA, et al. Economic cost and epidemiological characteristics of patients with fibromyalgia claims. J Rheumatol 2003; 30 (6): 1318–25PubMed

48.

Robinson RL, Birnbaum HG, Morley MA, et al. Depression and fibromyalgia: treatment and cost when diagnosed separately or concurrently. J Rheumatol 2004; 31 (8): 1621–9PubMed

49.

Berger A, Dukes E, Martin S, et al. Characteristics and healthcare costs of patients with fibromyalgia syndrome. Int J Clin Pract 2007; 61 (9): 1498–508PubMedCrossRef

50.

Penrod JR, Bernatsky S, Adam V, et al. Health services costs and their determinants in women with fibromyalgia. J Rheumatol 2004; 31 (7): 1391–8PubMed

51.

Annemans L, Wessely S, Spaepen E, et al. Health economic consequences related to the diagnosis of fibromyalgia syndrome. Arthritis Rheum 2008; 58 (3): 895–902PubMedCrossRef

52.

Hughes G, Martinez C, Myon E, et al. The impact of a diagnosis of fibromyalgia on health care resource use by primary care patients in the UK: an observational study based on clinical practice. Arthritis Rheum 2006; 54 (1): 177–83PubMedCrossRef

53.

Le Page JA, Iverson GL, Collins P. The impact of judges’ perceptions of credibility in fibromyalgia claims. Int J Law Psychiatry 2008; 31 (1): 30–40PubMedCrossRef

Titel: Societal and Patient Burden of Fibromyalgia Syndrome
verfasst von: Prof. Lieven Annemans
Katell Le Lay
Charles Taïeb
Publikationsdatum: 01.07.2009
Verlag: Springer International Publishing
Erschienen in: PharmacoEconomics / Ausgabe 7/2009
Print ISSN: 1170-7690
Elektronische ISSN: 1179-2027
DOI: https://doi.org/10.2165/11313650-000000000-00000

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Societal and Patient Burden of Fibromyalgia Syndrome

Abstract

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2009

Is it Time for Reporting Guidelines for Calibration Methods?

Calibration Methods Used in Cancer Simulation Models and Suggested Reporting Guidelines

Cost-Effectiveness Analysis of Capecitabine Compared with Bolus 5-Fluorouracil/l-Leucovorin for the Adjuvant Treatment of Colon Cancer in Japan

Costs of Illness in a Russian Cohort of Patients with Parkinson’s Disease

Economic Evaluations in the EURONHEED

Cost Utility of Adalimumab versus Infliximab Maintenance Therapies in the United States for Moderately to Severely Active Crohn’s Disease